Waltham, Massachusetts, USA-based biotech Morphic Therapeutic announced I a Securities and Exchange Commission (SEC) filing that Johnson & Johnson (NYSE: NJN) subsidiary Janssen Pharmaceuticals has elected to terminate the research collabora/tion and option agreement between the companies dated December 30, 2020, and as further expanded and amended.
The termination will be effective within 60 days of January 13, 2023.
https://www.thepharmaletter.com/article/morphic-reveals-that-janssen-has-terminated-agreement
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.